Skip to main content

Drug Interactions between brexanolone and C-Hist-SR

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

chlorpheniramine brexanolone

Applies to: C-Hist-SR (chlorpheniramine / phenylephrine / phenyltoloxamine) and brexanolone

Brexanolone may cause excessive sedation and sudden loss of consciousness during the infusion. The risk and/or severity may be increased when combined with other antidepressants or other medications that can also cause sedation. Let your doctor know prior to receiving brexanolone if you are currently using alcohol or receiving treatment with chlorpheniramine, as you may be more likely to experience sedation-related side effects. You should be under close medical supervision by a health care provider during administration of brexanolone. Tell your healthcare provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out. Your healthcare provider may lower your dose or stop the infusion until your symptoms go away. You must have a caregiver or family member with you to help care for your child(ren) during your brexanolone infusion. Do not drive, operate machinery, or engage in potentially hazardous activities requiring mental alertness and motor coordination until the sedative effects have gone away and you know how these medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

phenyltoloxamine brexanolone

Applies to: C-Hist-SR (chlorpheniramine / phenylephrine / phenyltoloxamine) and brexanolone

Brexanolone may cause excessive sedation and sudden loss of consciousness during the infusion. The risk and/or severity may be increased when combined with other antidepressants or other medications that can also cause sedation. Let your doctor know prior to receiving brexanolone if you are currently using alcohol or receiving treatment with phenyltoloxamine, as you may be more likely to experience sedation-related side effects. You should be under close medical supervision by a health care provider during administration of brexanolone. Tell your healthcare provider right away if you feel like you cannot stay awake during the time you are normally awake or if you feel like you are going to pass out. Your healthcare provider may lower your dose or stop the infusion until your symptoms go away. You must have a caregiver or family member with you to help care for your child(ren) during your brexanolone infusion. Do not drive, operate machinery, or engage in potentially hazardous activities requiring mental alertness and motor coordination until the sedative effects have gone away and you know how these medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

chlorpheniramine phenyltoloxamine

Applies to: C-Hist-SR (chlorpheniramine / phenylephrine / phenyltoloxamine) and C-Hist-SR (chlorpheniramine / phenylephrine / phenyltoloxamine)

Using chlorpheniramine together with phenyltoloxamine may increase side effects such as drowsiness, blurred vision, dry mouth, heat intolerance, flushing, decreased sweating, difficulty urinating, abdominal cramping, constipation, irregular heartbeat, confusion, and memory problems. Side effects may be more likely to occur in the elderly or those with a debilitating condition. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

chlorpheniramine food

Applies to: C-Hist-SR (chlorpheniramine / phenylephrine / phenyltoloxamine)

Alcohol can increase the nervous system side effects of chlorpheniramine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with chlorpheniramine. Do not use more than the recommended dose of chlorpheniramine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Moderate

phenyltoloxamine food

Applies to: C-Hist-SR (chlorpheniramine / phenylephrine / phenyltoloxamine)

Alcohol can increase the nervous system side effects of phenyltoloxamine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with phenyltoloxamine. Do not use more than the recommended dose of phenyltoloxamine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Moderate

phenylephrine food

Applies to: C-Hist-SR (chlorpheniramine / phenylephrine / phenyltoloxamine)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  4. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  5. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
View all 7 references

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.